Exicure Inc

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, California--(Newsfile Corp. - November 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exicure, Inc. ("Exicure" or "the Company") (NASDAQ: XCUR) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Exicure filed a Form 12b-25 with the SEC on November 15, 2021,...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Exicure--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) on behalf of Exicure stockholders. Our investigation concerns whether Exicure has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On November 15, 2021, after market hours, Exicure filed a Form 12b-25 wit

EXICURE ALERT: Bragar Eagel & Squire, P.C. is Investigating Exicure, Inc. on Behalf of Exicure Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Exicure investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Exicure, Inc. (XCUR) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) investors concerning the Company's possible violations of federal securities laws. On November 15, 2021, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report for the period ended September 30, 2021. It explained that the Company was investigating “a claim made by a former Company senior re

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Exicure, Inc. (XCUR) on Behalf of Investors

Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -68.75% and 559.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Exicure, Inc. (XCUR) Reports Q3 Loss, Lags Revenue Estimates

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress

Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress

LOS ANGELES--(BUSINESS WIRE)---- $XCUR #XCUR--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Exicure, Inc. (NASDAQ: XCUR) resulting from allegations that Exicure may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Exicure securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The R

EQUITY ALERT: Rosen Law Firm Encourages Exicure, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – XCUR

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Exicure investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, y

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Exicure, Inc. (XCUR) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $XCUR #investors--The Law Offices of Frank R. Cruz Announces Investigation of Exicure, Inc. (XCUR) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Exicure, Inc. (XCUR) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) investors concerning the Company's possible violations of federal securities laws. On November 15, 2021, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report for the period ended September 30, 2021. It explained that the Company was investigating “a claim made by a former Company senior res

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Exicure, Inc. (XCUR) on Behalf of Investors

Exicure Inc (NASDAQ: XCUR) has filed a Form 12b-25 with the U.S. SEC in connection with its Form 10-Q for the period ended September 30, 2021. On November 9, 2021, the Audit Committee of the Company's Board of Directors was notified of a claim regarding alleged improprieties for its XCUR-FXN preclinical program for Friedreich's ataxia.

Why Are Exicure Shares Trading At All Time Low?

The stock price of Exicure Inc (NASDAQ: XCUR) fell by over 25% pre-market today. This is why it happened.

Exicure (XCUR) Stock: Why The Price Substantially Dropped

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ: XCUR) today announced that it has filed a Form 12b-25 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the “Form 10-Q”). Exicure, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Q3 2021 10-Q”) with the SEC within the prescribed time period without unre

Exicure Files Form 12b-25

Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Exicure, Inc. (XCUR) Q3 Earnings Expected to Decline

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced presentations at TIDES EU and Neuroscience 2021 (The Society for Neuroscience).

Exicure to Present at Upcoming Scientific Conferences

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.

Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced participation in TIDES USA 2021 and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society.

Exicure to Participate in Upcoming Scientific Conferences

CHICAGO, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure to Participate in Upcoming Investor Conferences.

Exicure to Participate in Upcoming Investor Conferences

Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -6.67% and -92.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Exicure, Inc. (XCUR) Reports Q2 Loss, Misses Revenue Estimates

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress.

Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress

Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid tumors refractory to anti-PD-(L)1 therapy.  The trial is assessing cavrotolimod in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) or Sanofi SA (NASDAQ: SNY) - Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) in two primary dose-expansion cohorts, one in Merkel cell carcinoma (MCC) and one in cutaneous squamous cell carcinoma (CSCC), and three exploratory cohorts.

Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)

Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)

Analysts Estimate Exicure, Inc. (XCUR) to Report a Decline in Earnings: What to Look Out for

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021.

News for Exicure Inc Stock (XCUR)